Ocular adnexal lymphoma: validation of American Joint Committee on Cancer seventh edition staging guidelines.
OBJECTIVE
To validate the prognostic significance of the American Joint Committee on Cancer (AJCC) seventh edition staging criteria for ocular adnexal lymphoma (OAL) of all histologic subtypes.


METHODS
Retrospective review of clinical records for all consecutive patients with OAL treated from November 1998 to December 2012.


RESULTS
130 patients were evaluated, 82 with primary and 34 with secondary OAL. Fourteen patients were excluded due to incomplete records. 71 women (61.2%) and 45 men (38.8%) had a median age of 61.5 years. Patients were followed for a median of 32.5 months. Treatment varied, in part, related to lymphoma histologic subtype. Overall, there were 17 recurrences (8 local and 9 distant) in patients with primary OAL. For primary OAL, the 5-year disease-free survival (DFS) and overall survival (OS) rates were 55.9% and 85.8%, respectively. For primary OAL, while there was a trend towards decreased 5-year DFS for more aggressive subtypes, this was not statistically significant. More advanced Ann Arbor stage was associated with decreased 5-year DFS; however, this trend was not statistically significant. However, increased AJCC seventh edition T category was associated with decreased 5-year DFS (T1=67.8%, T2=59.2%, T3=28.6%, T4=33.3%; p=0.025).


CONCLUSIONS
AJCC seventh edition T category was predictive of DFS in patients with OAL.
Orbital Oncology and Ophthalmic Plastic and Reconstructive Surgery, Department of Plastic Surgery, Houston, Texasx, USA.
Matthew C
MC
Sniegowski
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Dianna
D
Roberts
Orbital Oncology and Ophthalmic Plastic and Reconstructive Surgery, Department of Plastic Surgery, Houston, Texasx, USA The University of Texas Medical Branch at Galveston, Galveston, Texas, USA.
Mathieu
M
Bakhoum
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Peter
P
Mc Laughlin
Orbital Oncology and Ophthalmic Plastic and Reconstructive Surgery, Department of Plastic Surgery, Houston, Texasx, USA.
Vivian T
VT
Yin
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Francesco
F
Turturro
Orbital Oncology and Ophthalmic Plastic and Reconstructive Surgery, Department of Plastic Surgery, Houston, Texasx, USA.
Bita
B
Esmaeli
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005134:Eye Neoplasms / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012008:Recurrence; D016019:Survival Analysis; D013781:Texas; D055815:Young Adult
Neoplasia; Orbit